About Us Strategy & Mission Our Values Our People Our Board Our Scientific Advisors Our Collaborations Contact Our Programs Pipeline C. difficile Infection Enterobacteriaceae Clinical Trials Our Science Discuva Platform Scientific Literature & Publications Investors Investor Center Press Releases Announcements, Financial Reports & Filings Email Alerts Share Price Data Analyst Coverage Corporate Governance Shareholder Meetings Careers
Ridinilazole Reduces Recurrence of Clostridium difficile Infection with Minimal Impact on the Gut Microbiota Ridinilazole Reduces Recurrence of Clostridium difficile Infection with Minimal Impact on the Gut Microbiota June 11, 2018 By CKD Digital
Ridinilazole Reduces Recurrence of Clostridium difficile Infection with Minimal Impact on the Gut Microbiota
Ridinilazole Reduces Recurrence of Clostridium difficile Infection with Minimal Impact on the Gut Microbiota June 11, 2018 By CKD Digital
